Logo image of MDXG

MIMEDX GROUP INC (MDXG) Stock Fundamental Analysis

NASDAQ:MDXG - Nasdaq - US6024961012 - Common Stock - Currency: USD

8  -0.09 (-1.05%)

After market: 8 0 (0%)

Fundamental Rating

6

MDXG gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. While MDXG has a great health rating, its profitability is only average at the moment. MDXG is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

MDXG had positive earnings in the past year.
In the past year MDXG had a positive cash flow from operations.
MDXG had negative earnings in 4 of the past 5 years.
MDXG had negative operating cash flow in 4 of the past 5 years.
MDXG Yearly Net Income VS EBIT VS OCF VS FCFMDXG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of 33.62%, MDXG belongs to the top of the industry, outperforming 99.12% of the companies in the same industry.
MDXG has a better Return On Equity (45.30%) than 99.12% of its industry peers.
MDXG's Return On Invested Capital of 24.79% is amongst the best of the industry. MDXG outperforms 99.12% of its industry peers.
Industry RankSector Rank
ROA 33.62%
ROE 45.3%
ROIC 24.79%
ROA(3y)-3.57%
ROA(5y)-13.45%
ROE(3y)-11.49%
ROE(5y)-40%
ROIC(3y)N/A
ROIC(5y)N/A
MDXG Yearly ROA, ROE, ROICMDXG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

1.3 Margins

With an excellent Profit Margin value of 23.92%, MDXG belongs to the best of the industry, outperforming 97.20% of the companies in the same industry.
The Operating Margin of MDXG (18.49%) is better than 95.97% of its industry peers.
In the last couple of years the Operating Margin of MDXG has remained more or less at the same level.
MDXG has a Gross Margin of 83.37%. This is amongst the best in the industry. MDXG outperforms 87.92% of its industry peers.
In the last couple of years the Gross Margin of MDXG has declined.
Industry RankSector Rank
OM 18.49%
PM (TTM) 23.92%
GM 83.37%
OM growth 3Y29.31%
OM growth 5Y-0.07%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.46%
GM growth 5Y-1.58%
MDXG Yearly Profit, Operating, Gross MarginsMDXG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MDXG is creating value.
MDXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MDXG Yearly Shares OutstandingMDXG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M
MDXG Yearly Total Debt VS Total AssetsMDXG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 13.67 indicates that MDXG is not in any danger for bankruptcy at the moment.
MDXG has a better Altman-Z score (13.67) than 90.54% of its industry peers.
MDXG has a debt to FCF ratio of 0.34. This is a very positive value and a sign of high solvency as it would only need 0.34 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.34, MDXG belongs to the top of the industry, outperforming 96.32% of the companies in the same industry.
MDXG has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of MDXG (0.10) is worse than 65.67% of its industry peers.
Even though the debt/equity ratio score it not favorable for MDXG, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.34
Altman-Z 13.67
ROIC/WACC2.65
WACC9.34%
MDXG Yearly LT Debt VS Equity VS FCFMDXG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

MDXG has a Current Ratio of 4.10. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
MDXG has a Current ratio of 4.10. This is comparable to the rest of the industry: MDXG outperforms 47.99% of its industry peers.
MDXG has a Quick Ratio of 3.53. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.53, MDXG perfoms like the industry average, outperforming 43.78% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.1
Quick Ratio 3.53
MDXG Yearly Current Assets VS Current LiabilitesMDXG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

MDXG shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.37%.
EPS 1Y (TTM)-9.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-84.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7%

3.2 Future

Based on estimates for the next years, MDXG will show a very strong growth in Earnings Per Share. The EPS will grow by 58.87% on average per year.
Based on estimates for the next years, MDXG will show a quite strong growth in Revenue. The Revenue will grow by 12.54% on average per year.
EPS Next Y9.03%
EPS Next 2Y22.98%
EPS Next 3Y58.87%
EPS Next 5YN/A
Revenue Next Year9.04%
Revenue Next 2Y10.4%
Revenue Next 3Y10.96%
Revenue Next 5Y12.54%

3.3 Evolution

MDXG Yearly Revenue VS EstimatesMDXG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M 500M
MDXG Yearly EPS VS EstimatesMDXG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 1

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 27.59, the valuation of MDXG can be described as expensive.
Based on the Price/Earnings ratio, MDXG is valued cheaply inside the industry as 95.27% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 29.71, MDXG is valued at the same level.
The Price/Forward Earnings ratio is 25.30, which means the current valuation is very expensive for MDXG.
93.17% of the companies in the same industry are more expensive than MDXG, based on the Price/Forward Earnings ratio.
MDXG is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.34, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 27.59
Fwd PE 25.3
MDXG Price Earnings VS Forward Price EarningsMDXG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

96.32% of the companies in the same industry are more expensive than MDXG, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, MDXG is valued cheaper than 95.62% of the companies in the same industry.
Industry RankSector Rank
P/FCF 21.09
EV/EBITDA 16.63
MDXG Per share dataMDXG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of MDXG may justify a higher PE ratio.
MDXG's earnings are expected to grow with 58.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.05
PEG (5Y)N/A
EPS Next 2Y22.98%
EPS Next 3Y58.87%

More info and screens

0

5. Dividend

5.1 Amount

MDXG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIMEDX GROUP INC

NASDAQ:MDXG (3/6/2025, 4:30:01 PM)

After market: 8 0 (0%)

8

-0.09 (-1.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2025-02-26/amc
Earnings (Next)04-28 2025-04-28/amc
Inst Owners70.4%
Inst Owner Change2.03%
Ins Owners2.22%
Ins Owner Change0.12%
Market Cap1.18B
Analysts81.82
Price Target13.67 (70.88%)
Short Float %2.6%
Short Ratio6.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.96%
Min EPS beat(2)11.41%
Max EPS beat(2)52.51%
EPS beat(4)4
Avg EPS beat(4)116.15%
Min EPS beat(4)11.41%
Max EPS beat(4)348.18%
EPS beat(8)8
Avg EPS beat(8)84.25%
EPS beat(12)9
Avg EPS beat(12)57.62%
EPS beat(16)12
Avg EPS beat(16)38.91%
Revenue beat(2)0
Avg Revenue beat(2)-2.1%
Min Revenue beat(2)-3.85%
Max Revenue beat(2)-0.35%
Revenue beat(4)2
Avg Revenue beat(4)0.13%
Min Revenue beat(4)-3.85%
Max Revenue beat(4)4.65%
Revenue beat(8)5
Avg Revenue beat(8)2.15%
Revenue beat(12)8
Avg Revenue beat(12)2.32%
Revenue beat(16)11
Avg Revenue beat(16)3.17%
PT rev (1m)0%
PT rev (3m)3.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)2.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 27.59
Fwd PE 25.3
P/S 3.43
P/FCF 21.09
P/OCF 20.38
P/B 6.49
P/tB 7.82
EV/EBITDA 16.63
EPS(TTM)0.29
EY3.62%
EPS(NY)0.32
Fwd EY3.95%
FCF(TTM)0.38
FCFY4.74%
OCF(TTM)0.39
OCFY4.91%
SpS2.33
BVpS1.23
TBVpS1.02
PEG (NY)3.05
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 33.62%
ROE 45.3%
ROCE 31.38%
ROIC 24.79%
ROICexc 44.25%
ROICexgc 60.68%
OM 18.49%
PM (TTM) 23.92%
GM 83.37%
FCFM 16.26%
ROA(3y)-3.57%
ROA(5y)-13.45%
ROE(3y)-11.49%
ROE(5y)-40%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-12.01%
ROICexcg growth 5YN/A
ROICexc growth 3Y5.84%
ROICexc growth 5Y-45.11%
OM growth 3Y29.31%
OM growth 5Y-0.07%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.46%
GM growth 5Y-1.58%
F-Score7
Asset Turnover1.41
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 0.34
Debt/EBITDA 0.27
Cap/Depr 50.16%
Cap/Sales 0.56%
Interest Coverage 250
Cash Conversion 85.78%
Profit Quality 67.97%
Current Ratio 4.1
Quick Ratio 3.53
Altman-Z 13.67
F-Score7
WACC9.34%
ROIC/WACC2.65
Cap/Depr(3y)65.35%
Cap/Depr(5y)58.37%
Cap/Sales(3y)1%
Cap/Sales(5y)1.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-84.37%
EPS Next Y9.03%
EPS Next 2Y22.98%
EPS Next 3Y58.87%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7%
Revenue Next Year9.04%
Revenue Next 2Y10.4%
Revenue Next 3Y10.96%
Revenue Next 5Y12.54%
EBIT growth 1Y177.7%
EBIT growth 3Y40.96%
EBIT growth 5Y-2.25%
EBIT Next Year226.71%
EBIT Next 3Y63.14%
EBIT Next 5Y48.92%
FCF growth 1Y431.96%
FCF growth 3YN/A
FCF growth 5Y-0.91%
OCF growth 1Y472.07%
OCF growth 3YN/A
OCF growth 5Y-5.64%